ADMA BIOLOGICS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ADMA Biologics, Inc. | ||
| Date: February 28, 2024 | By: | /s/ Adam S. Grossman |
|---|---|---|
| Name: | Adam S. Grossman | |
| Title: | President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Signature | Title | Date |
|---|---|---|
| /s/ Adam S. Grossman | ||
| Adam S. Grossman | President and Chief Executive Officer (Principal Executive Officer) and Director | February 28, 2024 |
| /s/ Brian Lenz | ||
| Brian Lenz | Executive Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | February 28, 2024 |
| /s/ Steven A. Elms | ||
| Steven A. Elms | Chairman of the Board of Directors | February 28, 2024 |
| /s/ Dr. Jerrold B. Grossman | ||
| Dr. Jerrold B. Grossman | Vice Chairman of the Board of Directors | February 28, 2024 |
| /s/ Alison Finger | ||
| Alison Finger | Director | February 28, 2024 |
| /s/ Bryant E. Fong | ||
| Bryant E. Fong | Director | February 28, 2024 |
| /s/ Lawrence P. Guiheen | ||
| Lawrence P. Guiheen | Director | February 28, 2024 |
| /s/ Young T. Kwon | ||
| Young T. Kwon | Director | February 28, 2024 |
CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 596) | F-3 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Operations for the years ended December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.